Media

Select from the drop-down menu below to read the most up-to-date news about pelareorep.

December 6, 2023 | Poster
T Cell Receptor Sequencing to Monitor Pelareorep-Induced Expansion of Tumor Infiltrating Lymphocytes 
Trauger, Richard et al, Previously presented at the 2023 San Antonio Breast Cancer Symposium®; December 5-9, 2023
November 3, 2023 | Poster
Analysis of the HR+/HER2- breast cancer tumor microenvironment following immune priming with pelareorep and atezolizumab using imaging mass cytometry – Results from the AWARE-1 trial
Olea, Julian et al. Previously presented at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting, November 1-5, 2023
October 3, 2023 | Poster
Multiplex analysis of the tumor immune microenvironment during treatment with atezolizumab/pelareorep/letrozole reveals novel immune-tumor interactions
Dadrastoussi, Homa et al.
December 1, 2022 | Poster
Pelareorep primes the tumor for checkpoint inhibition therapy by activating the interferon-gamma signaling pathway andtumor inflammation signature in early breast cancer patients – results of the AWARE-1 trial
H. Loghmani, J Gavila, L. Manso, R. Trauger, F. Salvador, T. Pascual, A. Prat, Matt Coffey, T. Heineman
November 8, 2022 | Poster
The oncolytic virus pelareorep in combination with immune checkpoint inhibitor activates T-cell functioning in early breast cancer patients – immunophenotype results from AWARE-1 study
González-Navarro, E.A et al, Previously presented at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting; November 8-12, 2022
May 3, 2022 | Poster
The oncolytic virus pelareorep primes the tumor microenvironment for checkpoint blockade therapy in early breast cancer patients – Results from AWARE-1 study
Gavilá, Joaquín et al, Previously presented at the European Society for Medical Oncology Breast Cancer 2022 Meeting; May 3-5, 2022
April 10, 2021 | Poster
A window-of-opportunity study with atezolizumab and the oncolytic virus pelareorep in early breast cancer (AWARE-1)
Manso L et al. In: AACR Virtual Annual Meeting 2021; 2021 Apr 10-15; Virtual. AACR; 2021. Abstract CT191
December 9, 2020 | Poster
A window-of-opportunity study with atezolizumab and the oncolytic virus pelareorep in early breast cancer (REO-027, AWARE-1)
Manso et al, Previously presented at the 2020 Virtual San Antonio Breast Cancer Symposium® - 43rd Annual Meeting;  San Antonio, TX, USA; December 9-11, 2020
November 1, 2020 | Poster
Changes in T cell clonality in AWARE-1 study, a window-of-opportunity study with atezolizumab and the oncolytic virus pelareorep in early breast cancer
Prat et al, SITC, 2020
September 1, 2020 | Poster
A window-of-opportunity Study with atezolizumab and the oncolytic virus pelareorep in early Breast Cancer (REO-027, AWARE-1)
Prat et al, ESMO Breast Cancer, 2020
November 1, 2019 | Poster
A window-of-opportunity Study of pelareorep in Early Breast Cancer (AWARE-1)
Prat Et al, SITC, 2019

Contact Us

For questions regarding our science, partnership opportunities, or other inquiries, we encourage you to reach out.

Get in touch